Development of New Deep Venous Thrombosis While on Apixaban.
Publication/Presentation Date
1-1-2017
Abstract
The efficacy of novel oral anticoagulants (NOACs) in preventing deep venous thrombosis (DVT) has been established in large multicenter trials. Predictable pharmacokinetics, avoidance of routine laboratory monitoring, and lesser drug interactions have made NOACs safer and more tolerable treatment option in comparison to warfarin. However, cases of treatment failure mainly due to interindividual variation in plasma drug levels can be seen rarely. In this report we describe a case of acute DVT of right lower extremity in a patient who was on apixaban for prevention of venous thromboembolism (VTE) due to underlying nonvalvular atrial fibrillation (NVAF).
Volume
2017
First Page
2842935
Last Page
2842935
ISSN
2090-6404
Published In/Presented At
Sharma, M., Ramanathan, S., & Khalighi, K. (2017). Development of New Deep Venous Thrombosis While on Apixaban. Case reports in cardiology, 2017, 2842935. https://doi.org/10.1155/2017/2842935
Disciplines
Medicine and Health Sciences
PubMedID
28713598
Department(s)
Department of Medicine, Cardiology Division
Document Type
Article